LISATA THERAPEUTICS INC. - COMMON STOCK

Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

10 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

13 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

28 May 2024 08:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

20 May 2024 08:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

09 May 2024 16:05:01 By Nasdaq GlobeNewswire

Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events

08 May 2024 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

02 May 2024 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

23 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

09 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

03 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

21 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

29 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time

22 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Present at BIO CEO & Investor Conference

20 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme

17 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy

04 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

12 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Present at NobleCon19 Investor Conference

28 Nov 2023 16:05:03 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Participation in Upcoming Conferences in November

09 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

02 Nov 2023 16:05:01 By Nasdaq GlobeNewswire